This is significanct because it is the first time a clinical trial ever reported success for Glioblastomas using targeted therapies. This is only for patients with a rare mutation known as v600E in the BRAF gene. The drugs are approved for other diseases so can be used off label right now:dabrafenib and trametinib. So check your pathology report - no matter what tumor type you have - for this mutation.
We have been using this combination for patients in our patient navigation program and have seen some good results!